Drug Safety

What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?
pp. 75-85(11)
Authors: Ozdemir V.; Shear N.H.; Kalow W.

Thalomid (Thalidomide) Capsules: A Review of the First 18 Months of Spontaneous Postmarketing Adverse Event Surveillance, Including Off-Label Prescribing
pp. 87-117(31)
Authors: Clark T.E.; Edom N.; Larson J.; Lindsey L.J.

Safety of Antihistamines in Children
pp. 119-147(29)
Authors: Ten Eick A.P.; Blumer J.L.; Reed M.D.

Troglitazone and Liver Function Abnormalities: Lessons from a Prescription Event Monitoring Study and Spontaneous Reporting
pp. 149-154(6)
Authors: Biswas P.; Wilton L.V.; Shakir S.A.

Incompleteness of Lamotrigine Data
pp. 155-156(2)
Authors: Acharya N.V.; Wilton L.V.; Shakir S.A.

Incompleteness of Lamotrigine Data: The Author's Reply
pp. 155-156(2)
Authors: Messenheimer J.A.; Risner M.E.; Giorgi L.